The NPM1 mutation, typically a favorable prognostic marker in newly diagnosed AML, loses this advantage in the relapsed/refractory setting. Survival for relapsed NPM1 patients becomes as poor as for those without the mutation, justifying aggressive targeted therapy with menin inhibitors.

Despite clinical efficacy, menin inhibitor monotherapy provides a relatively short duration of response (4-6 months) in the relapsed/refractory setting. Their main clinical benefit is achieving a deep enough remission to allow patients to proceed to a potentially curative allogeneic stem cell transplant.

When an AML patient presents with multiple targetable mutations (FLT3, NPM1, IDH), clinicians follow a treatment hierarchy. FLT3-targeted therapy is typically the first choice due to its aggressive phenotype. Menin inhibitors for NPM1 are next, followed by IDH inhibitors, guiding treatment decisions in complex cases.

Preclinical data and early clinical findings suggest menin inhibitors could be effective against rare NUP98-rearranged leukemias. This is based on similarities in downstream pathways to the approved KMT2A and NPM1 mutations, hinting at a broader mechanism of action for this drug class.

While adding a menin inhibitor to the azacitidine/venetoclax doublet for older/unfit AML patients increases response rates, it leaves little reserve for marrow function. This can lead to increased risk of early, fatal complications like infection or bleeding, requiring careful dose management.

Combining menin inhibitors with intensive chemotherapy can decrease the risk of differentiation syndrome, a severe side effect. The chemotherapy debulks the tumor, reducing the number of malignant cells available to cause this inflammatory reaction when they differentiate, improving tolerability.

The new menin inhibitor, enzomenib, demonstrates potentially superior response rates (CR/CRH of 40-60%) compared to existing agents (~23%). Crucially, early data shows no QTc prolongation, a significant dose-limiting toxicity for current menin inhibitors, suggesting a major safety improvement for this drug class.

Post-transplant maintenance strategy differs by mutation. For high-risk KMT2A-rearranged AML with less sensitive monitoring, maintenance is strongly considered. For NPM1-mutated AML, clinicians rely on highly sensitive qPCR for Minimal Residual Disease (MRD); if a patient is MRD-negative, they often forgo maintenance therapy.

Standard cytogenetics miss complex genetic rearrangements. Advanced techniques like Optical Genome Mapping (OGM) are identifying "cryptic" fusions (e.g., involving KMT2A, NUP98) in patients who appear to be wild-type. This expands the eligible patient pool for menin inhibitors beyond those with classic mutations.